148 related articles for article (PubMed ID: 36780200)
1. Pilot Study of Recurrent Ewing's Sarcoma Management with Vigil/Temozolomide/Irinotecan and Assessment of Circulating Tumor (ct) DNA.
Anderson P; Ghisoli M; Crompton BD; Klega KS; Wexler LH; Slotkin EK; Stanbery L; Manning L; Wallraven G; Manley M; Horvath S; Bognar E; Nemunaitis J
Clin Cancer Res; 2023 May; 29(9):1689-1697. PubMed ID: 36780200
[TBL] [Abstract][Full Text] [Related]
2. Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients.
Palmerini E; Jones RL; Setola E; Picci P; Marchesi E; Luksch R; Grignani G; Cesari M; Longhi A; Abate ME; Paioli A; Szucs Z; D'ambrosio L; Scotlandi K; Fagioli F; Asaftei S; Ferrari S
Acta Oncol; 2018 Jul; 57(7):958-964. PubMed ID: 29533113
[TBL] [Abstract][Full Text] [Related]
3. Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors.
Wagner L; Turpin B; Nagarajan R; Weiss B; Cripe T; Geller J
Pediatr Blood Cancer; 2013 Sep; 60(9):1447-51. PubMed ID: 23630159
[TBL] [Abstract][Full Text] [Related]
4. Three-year Follow up of GMCSF/bi-shRNA(furin) DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma.
Ghisoli M; Barve M; Mennel R; Lenarsky C; Horvath S; Wallraven G; Pappen BO; Whiting S; Rao D; Senzer N; Nemunaitis J
Mol Ther; 2016 Aug; 24(8):1478-83. PubMed ID: 27109631
[TBL] [Abstract][Full Text] [Related]
5. A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors.
Yoon JH; Kwon MM; Park HJ; Park SY; Lim KY; Joo J; Park BK
BMC Cancer; 2014 Aug; 14():622. PubMed ID: 25164234
[TBL] [Abstract][Full Text] [Related]
6. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R
Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
[TBL] [Abstract][Full Text] [Related]
7. SARC025 arms 1 and 2: A phase 1 study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma.
Chugh R; Ballman KV; Helman LJ; Patel S; Whelan JS; Widemann B; Lu Y; Hawkins DS; Mascarenhas L; Glod JW; Ji J; Zhang Y; Reinke D; Strauss SJ
Cancer; 2021 Apr; 127(8):1301-1310. PubMed ID: 33289920
[TBL] [Abstract][Full Text] [Related]
8. Irinotecan and temozolomide chemotherapy in paediatric and adult populations with relapsed Ewing Sarcoma.
Salah S; To YH; Khozouz O; Ismail T; Yaser S; Alnsour A; Shahin O; Sultan I; Abuhijlih R; Halalsheh H; Abuhijla F; Lewin J
Clin Transl Oncol; 2021 Apr; 23(4):757-763. PubMed ID: 32761317
[TBL] [Abstract][Full Text] [Related]
9. Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411).
Schafer ES; Rau RE; Berg SL; Liu X; Minard CG; Bishop AJR; Romero JC; Hicks MJ; Nelson MD; Voss S; Reid JM; Fox E; Weigel BJ; Blaney SM
Pediatr Blood Cancer; 2020 Feb; 67(2):e28073. PubMed ID: 31724813
[TBL] [Abstract][Full Text] [Related]
10. Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial.
Xu J; Xie L; Sun X; Liu K; Liang X; Cai Z; Tang X; Guo W
Clin Cancer Res; 2023 Mar; 29(6):1040-1046. PubMed ID: 36622702
[TBL] [Abstract][Full Text] [Related]
11. A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation.
Metts JL; Trucco M; Weiser DA; Thompson P; Sandler E; Smith T; Crimella J; Sansil S; Thapa R; Fridley BL; Llosa N; Badgett T; Gorlick R; Reed D; Gill J
Cancer Med; 2023 Feb; 12(4):4270-4281. PubMed ID: 36151773
[TBL] [Abstract][Full Text] [Related]
12. Vincristine, Irinotecan, and Temozolomide as a Salvage Regimen for Relapsed or Refractory Sarcoma in Children and Young Adults.
Ju HY; Park M; Lee JA; Park HJ; Park SY; Kim JH; Kang HG; Yang HC; Park BK
Cancer Res Treat; 2022 Apr; 54(2):563-571. PubMed ID: 34126703
[TBL] [Abstract][Full Text] [Related]
13. Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma.
Raciborska A; Bilska K; Drabko K; Chaber R; Pogorzala M; Wyrobek E; Polczyńska K; Rogowska E; Rodriguez-Galindo C; Wozniak W
Pediatr Blood Cancer; 2013 Oct; 60(10):1621-5. PubMed ID: 23776128
[TBL] [Abstract][Full Text] [Related]
14. Assessment of treatment responses in children and adolescents with Ewing sarcoma with metabolic tumor parameters derived from
Schmidkonz C; Krumbholz M; Atzinger A; Cordes M; Goetz TI; Prante O; Ritt P; Schaefer C; Agaimy A; Hartmann W; Rössig C; Fröhlich B; Bäuerle T; Dirksen U; Kuwert T; Metzler M
Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1564-1575. PubMed ID: 31853559
[TBL] [Abstract][Full Text] [Related]
15. Irinotecan plus temozolomide in relapsed Ewing sarcoma: an integrated analysis of retrospective studies.
Wang BC; Xiao BY; Lin GH
BMC Cancer; 2022 Mar; 22(1):349. PubMed ID: 35361149
[TBL] [Abstract][Full Text] [Related]
16. Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience.
Casey DA; Wexler LH; Merchant MS; Chou AJ; Merola PR; Price AP; Meyers PA
Pediatr Blood Cancer; 2009 Dec; 53(6):1029-34. PubMed ID: 19637327
[TBL] [Abstract][Full Text] [Related]
17. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma.
Wagner LM; McAllister N; Goldsby RE; Rausen AR; McNall-Knapp RY; McCarville MB; Albritton K
Pediatr Blood Cancer; 2007 Feb; 48(2):132-9. PubMed ID: 16317751
[TBL] [Abstract][Full Text] [Related]
18. Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study.
Subbiah V; Braña I; Longhi A; Boni V; Delord JP; Awada A; Boudou-Rouquette P; Sarantopoulos J; Shapiro GI; Elias A; Ratan R; Fernandez C; Kahatt C; Cullell-Young M; Siguero M; Zeaiter A; Chawla SP
Clin Cancer Res; 2022 Jul; 28(13):2762-2770. PubMed ID: 35486638
[TBL] [Abstract][Full Text] [Related]
19. Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer.
Rocconi RP; Stevens EE; Bottsford-Miller JN; Ghamande SA; Elder J; DeMars LL; Munkarah A; Aaron P; Stanbery L; Wallraven G; Bognar E; Manley M; Horvath S; Manning L; Walter A; Galanis E; Herzog T; Monk BJ; Coleman RL; Nemunaitis J
Cancer Gene Ther; 2022 Mar; 29(3-4):369-382. PubMed ID: 33753870
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies.
Federico SM; Pappo AS; Sahr N; Sykes A; Campagne O; Stewart CF; Clay MR; Bahrami A; McCarville MB; Kaste SC; Santana VM; Helmig S; Gartrell J; Shelat A; Brennan RC; Hawkins D; Godwin K; Bishop MW; Furman WL; Stewart E
Eur J Cancer; 2020 Sep; 137():204-213. PubMed ID: 32795876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
